profit from every $100 of sales.
$0$100
Envista
$25.32-2.01% today
+25.3% in 1 year
1-year low $18.951-year high $30.26
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $86.38 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Envista sold, what it kept, and what it did with the cash.
Sales went from $2.57 billion in 2022 to $2.72 billion in 2025, with $47.0 million of profit last year.
SalesProfit
Envista handed back 72% of the cash it generated last year.
Buybacks $167M
Free cash flow 2025$230M
Bought back its own shares$167M
Paid as dividends–
Cash vs. debt$1.2B vs. $1.6B
Envista vs. similar companies
Envista grows the slowest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Envista | 86.4× · Very expensive | ||
 Concentra Group Holdings Parent | 33.0× · Expensive | ||
 Hims & Hers Health | 38.0× · Expensive | ||
 Beta Bionics | No profit yet | ||
 CapsoVision | No profit yet |
Compare Envista with Dentsply Sirona
AI analysis
An AI analyst reads Envista's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2,569 | 2,567 | 2,511 | 2,720 | |
| 1,475 | 1,441 | 1,373 | 1,487 | |
| 343 | 315 | 137 | 236 | |
| 484 | 171 | -884 | 365 | |
| 243 | -100 | -1,119 | 47 | |
| 1.37 | -0.60 | -6.50 | 0.28 | |
| 57.4% | 56.1% | 54.7% | 54.7% | |
| 13.4% | 12.3% | 5.5% | 8.7% | |
| 9.5% | -3.9% | -44.6% | 1.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 6,587 | 6,605 | 5,351 | 5,679 |
| Cash | 607 | 940 | 1,069 | 1,212 |
| Total debt | 1,529 | 1,654 | 1,548 | 1,598 |
| Total liabilities | 2,380 | 2,431 | 2,416 | 2,573 |
| 4,207 | 4,174 | 2,935 | 3,106 | |
| 178 | 167 | 172 | 169 | |
| 4.4% | 0.1% | -18.3% | 3.6% | |
| 5.8% | -2.4% | -38.1% | 1.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 183 | 276 | 337 | 276 | |
| 76 | 58 | 34 | 45 | |
| 107 | 218 | 303 | 230 | |
| Dividends paid | – | – | – | – |
| – | 0 | 0 | 167 | |
| 31 | 31 | 35 | 38 |
Valuation
- 86.4×
- 17.9×
- –
- 1.2×
- 1.5×
- 17.6×
- 12.2×
- 5.7%
- 1.2%
- 0.0%
Profitability
- 54.7%
- 8.7%
- 1.7%
- 12.2%
- 1.8%
- -3.1%
- 2.2%
- 1.2%
- 5.3%
- 4.2%
Growth
- +1.9%
- −41.1%
- −23.9%
- –
- +1.0%
Financial health
- 1.5×
- 0.52
- 28.5%
- 12.8×
- 2.44
- 2.06
- 0.50
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 38%of 958
Bottom 48%of 889
Bottom 12%of 601
Bottom 21%of 890
Top 19%of 987
What analysts expect
- Average price target
- $27.00
- Range
- $19.00 – $35.00
- 7 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.36 | 0.31 | +16.1% |
| Feb 5, 2026 | 0.38 | 0.32 | +18.8% |
| Oct 29, 2025 | 0.32 | 0.27 | +18.5% |
| Jul 31, 2025 | 0.26 | 0.24 | +8.3% |
| May 1, 2025 | 0.24 | 0.20 | +20.0% |
| Feb 5, 2025 | 0.24 | 0.23 | +4.3% |
| Oct 30, 2024 | 0.12 | 0.09 | +33.3% |
| Aug 7, 2024 | 0.11 | 0.27 | −59.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
42No pass
Philip Fisher
24No pass
Peter Lynch
19No pass
Joel Greenblatt
16No pass
Charlie Munger
25No pass
Terry Smith
25No pass
Questions about Envista
Is Envista a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Envista AI analysis
What does Envista do?
Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. It is in Medical - Equipment & Services, based in Brea, CA, United States, with 12,000 employees.
Does Envista pay a dividend?
No. Envista does not pay a dividend at the moment; in 2025 it returned $167 million to shareholders by buying back its own shares.
Is Envista stock halal?
No. Envista does not pass our halal screen: its debt is 39% of its market value, at or above the 33% limit. How we check
How has Envista stock done over the past year?
Up 25.3% over the past twelve months, to $25.32. It traded between $18.95 and $30.26 and is 16.3% below its high.
Who are Envista's competitors?
The largest listed companies in the same industry are Concentra Group Holdings Parent, Hims & Hers Health, Beta Bionics and CapsoVision. The peers table on this page compares their profit, growth and price with Envista's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.